Staidson (Beijing) Pharmaceutical Co., Ltd (SHE: 300204), a biopharmaceutical company based in China, has announced that it has received clinical clearance from the National Medical Products Administration (NMPA) for its investigational STSP-0902 eye drops, which are intended for the treatment of neurotrophic keratitis (NK).
Neurotrophic keratitis, also referred to as neurotrophic keratopathy, is a rare corneal degenerative disease often resulting from trigeminal nerve damage. Characterized by reduced or absent corneal sensation, the condition can lead to dry eyes, corneal epithelial defects, and corneal ulcers, potentially progressing to corneal stromal dissolution and perforation. It is recognized as part of China’s second batch of rare diseases.
STSP-0902 is an in-house developed recombinant human nerve growth factor Fc fusion protein, currently under patent review in China and internationally. Preclinical data indicates that STSP-0902 has the ability to activate the TrkA receptor pathway, fostering nerve growth and enhancing corneal integrity and nerve length in preclinical models of neurotrophic keratitis. Furthermore, it has been shown to increase corneal perceptual sensitivity. Compared to recombinant wild-type human nerve growth factor, STSP-0902 also demonstrates a reduced potential to cause pain responses.- Flcube.com
